Fc-independent phagocytosis: Implications for intravenous IgG therapy in immune thrombocytopenia

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 4, 2008, Pages 278-282

  Webster, Michelle Lee ^a,b   Zhu, Guangheng ^b   Li, Yan ^a,b   Ni, Heyu ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Intravenous IgG; Phagocytosis; Platelets; Thrombocytopenia; Thrombosis

Indexed keywords

AUTOANTIBODY; FIBRINOGEN RECEPTOR; GAMIMMUNE; GLYCOPROTEIN IB; GLYCOPROTEIN IB ALPHA; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; THROMBOCYTE ANTIGEN; UNCLASSIFIED DRUG; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; THROMBIN RECEPTOR;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; APOPTOSIS; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING; BLOOD CELL; CELL INTERACTION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TREATMENT FAILURE; HEART INFARCTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INNATE IMMUNITY; LEUKOCYTE FUNCTION; MACROPHAGE FUNCTION; NEUTROPHIL; NONHUMAN; OPSONIZATION; PETECHIA; PHAGOCYTE; PHAGOCYTOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETICULOENDOTHELIAL SYSTEM; RETROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; METABOLISM; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PHAGOCYTOSIS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, FC; THROMBOCYTOPENIA;

EID: 60549088702     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908786786223     Document Type: Article

References (59)

1. Metchnikoff, M.E. Sur la lutte des cellules de l'organisme contre l'invasion des microbes. Ann. Inst. Pasteur., 1887, 1, 321-336.
2. Netski, D.; Kozel, T.R. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity. Infect. Immun., 2002, 70, 2812-9.
3. Fujiwara, N.; Kobayashi, K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy, 2005, 4, 281-6.
4. Pluddemann, A.; Mukhopadhyay, S.; Gordon, S. The interaction of macrophage receptors with bacterial ligands. Expert. Rev. Mol. Med., 2006, 8, 1-25.
5. Pluddemann, A.; Neyen, C.; Gordon, S. Macrophage scavenger receptors and host-derived ligands. Methods, 2007, 43, 207-17.
6. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun., 1998, 66, 277-81.
7. Collins, H.L.; Kaufmann SH. The many faces of host responses to tuberculosis. Immunology, 2001, 103, 1-9.
8. Faller, D.V.; Mentzer, S.J. Monocyte and macrophage development and function. In Hematology - Basic Principles and Practice (R. Hoffman, E. J. J. Benz, S. J. Shattil, B. Furie, H. J. Cohen, L. E. Silberstein and P. McGlave, eds), Churchill-Livingstone, New York, 2000; 686-701.
9. Garratty, G. Effect of cell-bound proteins on the in vivo survival of circulating blood cells. Gerontology, 1991, 37, 68-94.
10. Coopamah, M.D.; Freedman, J.; Semple, J.W. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood, 2003, 102, 2862-7.
11. Lee, J.C.; Tripathy, K. Neutrophilic thrombophagocytosis. Arch. Pathol. Lab. Med., 2000, 124, 1545-6.
12. Ni, H.; Freedman, J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus. Apher. Sci., 2003, 28, 257-64.
13. Ni, H.; Papalia, J.M.; Degen, J.L.; Wagner, D.D. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood, 2003, 102, 3609-14.
14. Wu, Y.; Tibrewal, N.; Birge, R.B. Phosphatidylserine recognition by phagocytes: A view to a kill. Trends Cell Biol., 2006, 16, 189-97.
15. Leung, R.; Gwozdz, A.M.; Wang, H.; Bang, K.W.; Packham, M.A.; Freedman, J.; Rand, M.L. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J. Thromb. Haemost., 2007, 5, 560-70.
16. Rand, M.L.; Wang, H.; Bang, K.W.; Poon, K.S.; Packham, M.A.; Freedman, J. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J. Thromb. Haemost., 2004, 2, 651-9.
17. Chow, L.; Ni, H.; Kim, M.; Speck, E.R.; Aslam, R.; Chen, P.; Freedman, J.; Semple, J.W. A new murine model of immune thrombocytopenia: evidence of both antibody- and CD8+ T cell-mediated platelet destruction. Blood, 2007, 110, 38a.
18. Olsson, B.; Andersson, P.O.; Jernas, M.; Jacobsson, S.; Carlsson, B.; Carlsson, L.M.; Wadenvik, H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med., 2003, 9, 1123-4.
19. Zhang, F.; Chu, X.; Wang, L.; Zhu, Y.; Li, L.; Ma, D.; Peng, J.; Hou, M. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur. J. Haematol., 2006, 76, 427-31.
20. Bussel, J.; Cines, D. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenia, and posttransfusion purpura. In Hematology - Basic Principles and Practice (R. Hoffman, E. J. J. Benz, S. J. Shattil, B. Furie, H. J. Cohen and L. E. Silberstein, eds), Churchill-Livingstone, New York 2096-2114, 2000.
21. Harrington, W.J.; Minnich, V.; Hollingsworth, J.W.; Moore, C.V. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. 1951. J. Lab. Clin. Med., 1990, 115, 636-45.
22. McMillan, R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin. Hematol., 2000, 37, 239-48.
23. Ni, H.; Chen, P.; Spring, C.M.; Sayeh, E.; Semple, J.W.; Lazarus, A.H.; Hynes, R.O.; Freedman, J. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood, 2006, 107, 2976-83.
24. McMillan, R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin. Hematol., 2000, 37, 5-9.
25. Beardsley, D.S.; Ertem, M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus. Sci., 1998, 19, 237-44.
26. He, R.; Reid, D.M.; Jones, C.E.; Shulman, N.R. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood, 1994, 83, 1024-32.
27. Kiefel, V.; Santoso, S.; Kaufmann, E.; Mueller-Eckhardt, C. Autoantibodies against platelet glycoprotein Ib/IX: a frequent finding in autoimmune thrombocytopenic purpura. Br. J. Haematol., 1991, 79, 256-62.
28. McMillan, R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J. Pediatr. Hematol. Oncol., 2003, 25 Suppl. 1, S57-61.
29. Hynes, R.O. Fibronectin, Springer Verlag, New York, 1990.
30. Lopez, J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul. Fibrinolysis, 1994, 5, 97-119.
31. Modderman, P.W.; Admiraal, L.G.; Sonnenberg, A.; von dem Borne, A.E. Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. J. Biol. Chem., 1992, 267, 364-9.
32. Bergmeier, W.; Piffath, C.L.; Goerge, T.; Cifuni, S.M.; Ruggeri, Z.M.; Ware, J.; Wagner, D.D. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl. Acad. Sci. USA, 2006, 103, 16900-5.
33. Ruggeri, Z.M. Platelets in atherothrombosis. Nat. Med., 2002, 8, 1227-34.
34. Ruggeri, Z.M. Von Willebrand factor, platelets and endothelial cell interactions. J. Thromb. Haemost., 2003, 1, 1335-42.
35. Kasirer-Friede, A.; Cozzi, M.R.; Mazzucato, M.; De Marco, L.; Ruggeri, Z.M.; Shattil, S.J. (2004) Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood, 2004, 103, 3403-11.
36. Ozaki, Y.; Asazuma, N.; Suzuki-Inoue, K.; Berndt, M.C. Platelet GPIb-IX-V-dependent signaling. J. Thromb. Haemost., 2005, 3, 1745-51.
37. Yang, H.; Reheman, A.; Chen, P.; Zhu, G.; Hynes, R.O.; Freedman, J.; Wagner, D.D.; Ni, H. Fibrinogen and von Willebrand factor- independent platelet aggregation in vitro and in vivo. J. Thromb. Haemost., 2006, 4, 2230-7.
38. Shattil, S.J.; Newman, P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood, 2004, 104, 1606-15.
39. Jy, W.; Horstman, L.L.; Arce, M.; Ahn, Y.S. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J. Lab. Clin. Med., 1992, 119, 334-45.
40. Olsson, A.; Andersson, P.O.; Tengborn, L.; Wadenvik, H. Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function. Thromb. Res., 2002, 107, 135-9.
41. Yanabu, M.; Ozaki, Y.; Nomura, S.; Miyake, T.; Miyazaki, Y.; Kagawa, H.; Yamanaka, Y.; Asazuma, N.; Satoh, K.; Kume, S.; Komiyama, Y.; Fukuhara, S. Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody. Blood, 1997, 89, 1590-8.
42. Nieswandt, B.; Bergmeier, W.; Rackebrandt, K.; Gessner, J.E.; Zirngibl, H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood, 2000, 96, 2520-7.
43. Amital, H., Swissa, M., Bar-Dayan, Y., Buskila, D., Shoenfeld, Y. New therapeutic avenues in autoimmunity. Res. Immunol., 1996, 147, 361-76.
44. Godeau, B.; Lesage, S.; Divine, M.; Wirquin, V.; Farcet, J.P.; Bierling, P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood, 1993, 82, 1415-21.
45. Imbach, P.; Barandun, S.; Baumgartner, C.; Hirt, A.; Hofer, F.; Wagner, H.P. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv. Paediatr. Acta, 1981, 36, 81-6.
46. Stangel, M.; Hartung, H.P.; Marx, P.; Gold, R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J. Neurol. Sci., 1998, 153, 203-14.
47. Ephrem, A.; Misra, N.; Hassan, G.; Dasgupta, S.; Delignat, S.; Van Huyen, J.P.; Chamat, S.; Prost, F.; Lacroix-Desmazes, S.; Kavery, S.V.; Kazatchkine, M.D. Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin. Clin. Exp. Med., 2005, 5, 135-40.
48. Lazarus, A.H.; Crow, A.R. Mechanism of action of IVIG and anti- D in ITP. Transfus. Apher. Sci., 2003, 28, 249-55.
49. Crow, A.R.; Lazarus, A.H. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J. Pediatr. Hematol. Oncol., 2003, 25, Suppl. 1, S14-8.
50. Negi, V.S.; Elluru, S.; Siberil, S.; Graff-Dubois, S.; Mouthon, L.; Kazatchkine, M.D.; Lacroix-Desmazes, S.; Bayry, J.; Kaveri, S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol., 2007, 27, 233-45.
51. Nimmerjahn, F.; Ravetch, J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med., 2007, 204, 11-5.
52. Provan, D.; Newland, A. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults. Br. J. Haematol., 2002, 118, 933-44.
53. Crow, A.R.; Song, S.; Semple, J.W.; Freedman, J.; Lazarus, A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br. J. Haematol., 2001, 115, 679-86.
54. Nimmerjahn, F.; Ravetch, J.V. Fcgamma receptors: old friends and new family members. Immunity, 2006, 24, 19-28.
55. Nimmerjahn, F.; Bruhns, P.; Horiuchi, K.; Ravetch, J.V. FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity, 2005, 23, 41-51.
56. Webster, M.L.; Sayeh, E.; Crow, M.; Chen, P.; Nieswandt, B.; Freedman, J.; Ni, H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood, 2006, 108, 943-6.
57. Go, R.S.; Johnston, K.L.; Bruden, K.C. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica, 2007, 92, 283-4.
58. Hefer, D.; Jaloudi, M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann. Hematol., 2004, 83, 661-5.
59. Itkin, Y.M.; Trujillo, T.C. Intravenous immunoglobulin-associated acute renal failure: case series and literature review. Pharmacotherapy, 2005, 25, 886-92.